DURECT CORPORATION (NASDAQ:DRRX) Files An 8-K Other Events
Item 8.01 Other Events
On April 24, 2017, DURECT Corporation, a Delaware corporation
(DURECT), issued a press release announcing presentation of data
from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis
(NASH) at The International Liver Congress 2017. A copy of
DURECTs press release is attached as Exhibit 99.1 hereto and
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
99.1 |
Press Release of DURECT Corporation dated April 24, 2017 |
About DURECT CORPORATION (NASDAQ:DRRX)
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. DURECT CORPORATION (NASDAQ:DRRX) Recent Trading Information
DURECT CORPORATION (NASDAQ:DRRX) closed its last trading session up +0.005 at 0.891 with 241,223 shares trading hands.
